The report discusses the use of Ebola vaccines and the role of the International Coordinating Group (ICG) on vaccine provision during 2021-2023. Two licensed vaccines, rVSVAG-ZEBOV-GP (ERVEBO) and Ad26.ZEBOV and MVA-BN-Filo (Zabdeno/Mvabea), are available for preventing Ebola caused by *Orthoebovirus zairensis*. ERVEBO, a 1-dose vaccine, was recommended by the Strategic Advisory Group of Experts on Immunization (SAGE) for use during Ebola outbreaks, and a global stockpile of ERVEBO was established in 2021 to ensure equitable, timely access for future outbreaks. Since 2021, 145,690 doses have been shipped from the ICG stockpile, with most doses (95%) repurposed for preventive vaccination of high-risk groups, while only 5% were used for outbreak response. Ensuring sufficient vaccine doses for emergency outbreak response remains a priority, but investments, advocacy, and additional research are crucial for health system preparedness and resilience. The report highlights the importance of preventive vaccination campaigns targeting healthcare and front-line workers in at-risk countries, which could reduce case numbers, hospitalizations, and deaths by 14-38%. Innovative strategies, such as post-outbreak vaccination of close contacts of survivors, are also discussed to protect Ebola survivors and prevent reintroduction.The report discusses the use of Ebola vaccines and the role of the International Coordinating Group (ICG) on vaccine provision during 2021-2023. Two licensed vaccines, rVSVAG-ZEBOV-GP (ERVEBO) and Ad26.ZEBOV and MVA-BN-Filo (Zabdeno/Mvabea), are available for preventing Ebola caused by *Orthoebovirus zairensis*. ERVEBO, a 1-dose vaccine, was recommended by the Strategic Advisory Group of Experts on Immunization (SAGE) for use during Ebola outbreaks, and a global stockpile of ERVEBO was established in 2021 to ensure equitable, timely access for future outbreaks. Since 2021, 145,690 doses have been shipped from the ICG stockpile, with most doses (95%) repurposed for preventive vaccination of high-risk groups, while only 5% were used for outbreak response. Ensuring sufficient vaccine doses for emergency outbreak response remains a priority, but investments, advocacy, and additional research are crucial for health system preparedness and resilience. The report highlights the importance of preventive vaccination campaigns targeting healthcare and front-line workers in at-risk countries, which could reduce case numbers, hospitalizations, and deaths by 14-38%. Innovative strategies, such as post-outbreak vaccination of close contacts of survivors, are also discussed to protect Ebola survivors and prevent reintroduction.